CERS Long Call Strategy
CERS (Cerus Corporation), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America.
CERS (Cerus Corporation) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $546.1M, a beta of 1.77 versus the broader market, a 52-week range of 1.15-3.47, average daily share volume of 2.6M, a public-listing history dating back to 1997, approximately 268 full-time employees. These structural characteristics shape how CERS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.77 indicates CERS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on CERS?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
CERS snapshot
As of August 14, 2026, spot at $3.00, ATM IV 68.30%, IV rank 10.77%, expected move 19.58%. The long call on CERS below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this long call structure on CERS specifically: CERS IV at 68.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a CERS long call, with a market-implied 1-standard-deviation move of approximately 19.58% (roughly $0.59 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CERS expiries trade a higher absolute premium for lower per-day decay. Position sizing on CERS should anchor to the underlying notional of $3.00 per share and to the trader's directional view on CERS stock.
CERS long call setup
The CERS long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CERS at $3.00 on that close, the first option leg uses a $3.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CERS chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CERS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $3.00 | N/A |
CERS long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
CERS long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on CERS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on CERS
Long calls on CERS express a bullish thesis with defined risk; traders use them ahead of CERS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
CERS thesis for this long call
The market-implied 1-standard-deviation range for CERS extends from approximately $2.41 on the downside to $3.59 on the upside. A CERS long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CERS IV rank near 10.77% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CERS at 68.30%. As a Healthcare name, CERS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CERS-specific events.
CERS long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CERS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CERS alongside the broader basket even when CERS-specific fundamentals are unchanged. Long-premium structures like a long call on CERS are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CERS chain quotes before placing a trade.
Frequently asked questions
- What is a long call on CERS?
- A long call on CERS is the long call strategy applied to CERS (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CERS stock at $3.00 on the most recent close, the strikes shown on this page are snapped to the nearest listed CERS chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are CERS long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CERS long call priced from the end-of-day chain at a 30-day expiry (ATM IV 68.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CERS long call?
- The breakeven for the CERS long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CERS market-implied 1-standard-deviation expected move in the same options snapshot is approximately 19.58%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on CERS?
- Long calls on CERS express a bullish thesis with defined risk; traders use them ahead of CERS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current CERS implied volatility affect this long call?
- CERS ATM IV is at 68.30% with IV rank near 10.77%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.